{"name":"Curacle Co., Ltd.","slug":"curacle-co-ltd","ticker":"","exchange":"","domain":"curacle.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CU06-1004, Single dose","genericName":"CU06-1004, Single dose","slug":"cu06-1004-single-dose","indication":"Other","status":"phase_1"},{"name":"CU104","genericName":"CU104","slug":"cu104","indication":"Other","status":"phase_2"},{"name":"CU06-1004","genericName":"CU06-1004","slug":"cu06-1004","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CU06-1004, Single dose","genericName":"CU06-1004, Single dose","slug":"cu06-1004-single-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CU104","genericName":"CU104","slug":"cu104","phase":"phase_2","mechanism":"CU104 is an investigational drug with unknown mechanism of action.","indications":[],"catalyst":""},{"name":"CU06-1004","genericName":"CU06-1004","slug":"cu06-1004","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOY3UwTFY2ZGI5ZXJNUEJVZ3o0ZThCdTFOWm5uN0t4QU0xOUVrOU8ySndNOER3Y2VhVWlDZUJZcWxlc3FpQUFzNERwdTEzdjJyTllyalNuVmwzbEJzX1RUN3hpUDZWZkg0X3VxZmRfYlhhS1M5VDZrLWRxZEJBdFkzSlpFU2NJY2VnRTBGMl9kT2l1aURLbXhLbGtfQXFqWU0wWllEV2RkdkN0TndsbE1iVzZWX1lReXFYZkNTaVJuQUJlXzFQSi1HNjA0Ti1kaVNDcUE4QXBJZU1OUVV3Znk3aHZjdmxMR0pLYjJMUzhPNE51SlcwVGVZcm5DSFl1UGYwb0t2SmJlM0l6TC16TV8ydTNsZlRqanRhbUxsbk9maU82RVpiSmRzeg?oc=5","date":"2025-06-10","type":"trial","source":"GlobeNewswire","summary":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights - GlobeNewswire","headline":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOOVJIenVNc1MxWVNqRWRocE9QdkZVbGd6WUl3endxV2FUeUJFeUJ0OGpRU2ZhaFZ0Q2RZZldicHhaLThBZ3BiblBzTjFRTERQdlA4bkZOMTE3UElFNUtZM1g1Ql9QZWJQbVpmYVVqMk50YV9hVENvWWwzQktIVHNNR3hoeW9haTlFakE1TURTY2luR3FJX3cxTDZOR0VOYTMxRGRydTllNnZMNlZnTmhCbnBfbDl5a1BSbG1zbnVXYWgzcmdx?oc=5","date":"2024-12-09","type":"regulatory","source":"Modern Retina","summary":"DelveInsight releases report of in-depth background and trends of the diabetic macular edema - Modern Retina","headline":"DelveInsight releases report of in-depth background and trends of the diabetic macular edema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBId3IxY1Z1NXRzWDZSemZyNzNQRjI0Q2M1SGVLQWdZeGJDSTJ6UmJyd1pwdkJfeEtHM2lnUVBmSHNvbi1EWVpxbzhRSkFPVjFDQVBzQkVGOXFNekJiSXlCb1BCVFBnSjBCYWlwdkln0gFyQVVfeXFMUEd6UDdOLVBOVWpzWFBaVDVsSmRic3RhSDZxM3U1ekZJWF9oQWNBVDM1WHBmRzNhUkR4OHAwcGtUNGlpX3JjN0hWU3Y5c0ltcy1wS0hfMkRmbzNnWURTVDJrMVZFb2E0a0NsTWZzOXdmUVFn?oc=5","date":"2024-06-24","type":"pipeline","source":"koreabiomed.com","summary":"OliX Pharmaceuticals shares plunge 17% following failed licensing agreement - koreabiomed.com","headline":"OliX Pharmaceuticals shares plunge 17% following failed licensing agreement","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}